May 2018 Special Edition
Volume 4, Issue 6.1
This supplement features FDA updates, clinical trials, and the latest research in myeloid malignancies.
Table of Contents
Newly Approved Drugs
The Year in FDA Approvals
In the past year, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of myeloid malignancies, including drugs approved for...
Features
Beyond Ruxolitinib: Exploring the JAK Inhibitors Landscape
In 2011, the U.S. Food and Drug Administration (FDA) approved ruxolitinib as the first therapy to treat myelofibrosis (MF), one of the group of...
Myeloid Malignancies: The Next Frontier for Immunotherapy
Building on the success of chimeric antigen receptor (CAR) T-cell therapies in lymphocytic leukemia and certain lymphomas – and the advances seen with checkpoint...
Determining CHIP’s Potential
Researchers have known about clonal hematopoiesis – clonal expansion among hematopoietic stem cells , resulting in a population of genetically identical blood cells) for...
In the Literature
Final Results From PERSIST-2: Pacritinib Superior to Best Available Therapy in Patients With Myelofibrosis...
The development of the JAK2/FLT3 inhibitor pacritinib has been marked by ups and downs. In the phase III PERSIST-1 and PERSIST-2 trials, the drug...
CRISPR Gene Editing Puts Researchers Closer to an “Off-the-Shelf” CAR T-Cell Product for ALL
Last year marked the first U.S. Food and Drug Administration approvals of autologous T-cell immunotherapies for the treatment of cancer, including acute lymphocytic leukemia...
The Genetic Signatures of AML Vary Between Younger and Older Patients
Acute myeloid leukemia (AML) is a collection of molecularly diverse diseases with similar phenotypes, and the distribution of these diseases differs between children and...
